ABSTRACT
INTRODUCTION
According to the Alzheimer's Association in 2013, one of eight Americans older than 60 has memory impairments [1] . The number of patients suffering from Alzheimer's disease (AD) has been constantly growing in different parts of the world. In the US alone, the number of patients with AD aged 65 and older is expected to increase from 5.4 million to 13.8 -16 million by 2050 [2] .
AD has for long been considered a purely neurodegenerative disease, so the research has mainly focused on structural changes in the brain tissue during this disease [3] [4] [5] . The introduction of such radiological methods as CT, MRI and PET has made great progress in neuroimaging allowing to study in vivo the changes that occur in the brain tissue during various neurodegenerative processes as well as to differentiate various structural lesions [6] [7] [8] [9] . The use of biomarkers in the diagnosis of AD has recently allowed visualizing the accumulation of amyloid-beta and tau [10] [11] [12] [13] .
and described dysoric or drusoidal angiopathy [14] . His extremely important study went unnoticed, and there has been practically no research in this area [15] . Only recently there have appeared significant studies aimed at investigating cerebral blood flow abnormalities in AD [16] [17] [18] [19] [20] [21] which has resulted in the overall recognition of the fact that hypoperfusion and changes in the morphology of capillaries are involved in the etiology and pathogenesis of AD [22] [23] [24] [25] [26] [27] [28] .
As a result, there have appeared several hypotheses concerning the role of microvascular changes in the etiopathogenesis of the disease [28] [29] [30] [31] [32] [33] [34] [35] [36] which points to the need for further research in this area. It has recently been repeatedly stated in the guidelines of the National Institute on Aging/Alzheimer's Association [37, 38] .
The ongoing studies are mainly based on post-mortem autopsy material [39, 40] , research on genetically modified animals [26, 28, 41] , identification of cerebral perfusion by means of scintigraphy (SG) [42] , single-photon emission computed tomography (SPECT), positron emission tomography (PET) [27, 43] , perfusion weighted magnetic resonance imaging (Perfusion MRI or PWI) [27] .
All these methods have their pros and cons, but they do not reflect the true antemortem state of arterial, venous and microvascular system of the brain in AD.
Pathomorphological research allows of histological, cytological and cytochemical analysis of the brain. Research conducted on transgenic animals allows to explore models of the disease. Antemortem study of cerebral blood flow abnormalities is difficult enough. SPECT, PET and Perfusion MRI demonstrate average results and show the perfusion of the whole brain being unable to visualize the cerebral vascular system. The present research focuses on visualizing by means of MUGA the features of cerebral angioarchitectonics and on microcirculatory disorders occurring at both preclinical AD stage and during its progress, as well as on comparison of these disorders with the changes in the vascular system of the brain in patients suffering from other common neurodegenerative diseases. The objective of this research is to systematize cerebrovascular disorders in AD.
METHODS

Patient Selection
The whole research has been carried out with the approval of the Ethics Committee and with the consent of the examined patients and their relatives.
The research involved 164 patients from 28 to 79 years old (average age 67.5), 76 (46.34%) male and 88 (53.66%) female patients, suffering from various neurodegenerative brain lesions accompanied by the development of dementia and cognitive impairment of varying severity.
Patient Examination
The examination plan included the following methods:
• Assessment of cognitive functions was conducted by means of Mini-Mental State Examination (MMSE) [44] .
• Clinical determination of the severity of dementia was made according to the Clinical Dementia Rating scale (CDR) [45] .
• Tomographic identification of AD stages was performed among Test Group patients using the Tomography Dementia Rating scale (TDR) during CT and MRI examination [46] [47] [48] [49] . This method allows to determine not only clinical but also pre-clinical AD stages by the determination of the severity of atrophic changes in the temporal lobes of the brain.
• Laboratory examination was performed according to the schemes generally accepted in iterventional neuroangiology including coagulologic, biochemical and clinical tests.
• Scintigraphy (SG) of the brain was carried out on a gamma camera (Ohio Nuclear, US) following the classical method in dynamic and static mode with TC 99M pertechnetat 555 [20, 21, 30, 32] .
• Rheoencephalography (REG) was conducted by means of "Reospektr-8" (Neurosoft, Russia) in accordance with the standard automated method with the identification of abnormalities of pulse blood flow in the cerebral hemispheres [22, 32] .
• CT and MRI of the brain were performed on "Somatom" (Siemens), "Hi Speed" (GE), "Tomoscan" (Philips), "Apetro Eterna" (Hitachi) following the ATAA (Advance Tomo Area Analysis) procedure allowing to determine the volume of the temporal lobes of the brain with subsequent determination of the severity of the degree of atrophy as a percentage from the total natural weight of the unaffected lobe tissue [21, [46] [47] [48] .
• Cerebral multi-gated angiography (MUGA) of the brain was performed on apparatus "Advantx" (GE) following the classical method of transfemoral access. Synchronously, taking into account the start and rate of administration, 10 -12 ml of Omnipack 350 was introduced intra-carotidally and 7 -8 ml intra-vertebrally. The registration was carried out in direct and side projections in constant subtraction mode at a speed of 25 frames per second. Further on, frame by frame analysis of the angiograms received in each phase contrast was conducted [20, 21, 32, 42] . Capillary density contrast analysis was performed at the corresponding phase by means of an automatic method using computer program "Angio vision" based on the determination of the degree of blackening of the corresponding part of the image [20, 21, 42] . mild cognitive impairment, had previously been diagnosed with AD, history of the disease did not to exceed 2 years, the atrophy of the temporal lobes was 9% -18% which corresponds to CDR-1 (20 -25 MMSE points)-24 (29.63%) patients; • Middle AD stage-TDR-2: a group with mild dementia, sufficiently persistеnt cognitive impairment, had previously been diagnosed with AD, medical history of 2 to 6 years, the atrophy of the temporal lobes was 19% -32% which corresponds to CDR-2 (12 -19 MMSE points)-31 (38.27%) patients; • Late AD stage-TDR-3: a group with fairly severe dementia, gross cognitive impairment, had previously been diagnosed with AD, medical history of 7 to 12 years, the atrophy of the temporal lobes was 33% -62% which corresponds to CDR-3 (7-11 MMSE points)-17 (20.99%) patients.
Test Group
Control Group
83 (50.61%) patients from 28 to 78 years of age (av-erage age 68), 48 (57.83%) male and 35 (42.17%) female patients, with etiologically different neurodegenerative brain lesions accompanied by manifestations of dementia and cognitive impairment of varying severity but without AD.
These patients were divided into the following groups: • A group with the initial stage of chronic cerebrovascular insufficiency of atherosclerotic genesis without any signs of persistent dementia or cognitive impairment. Those patients had individual complaints revealing abnormalities of cerebral hemodynamics-19 (22.89%) patients of whom 7 patients had CDR-1; • A group with sufficiently severe chronic cerebrovascular insufficiency of atherosclerotic genesis without gross occlusive vascular lesions of the brain. Those patients had MCI and the symptoms of mild beginning dementia-18 (21.69%) patients of whom 13 had CDR-1 and 5 had CDR-2; • A group with multiple atherosclerotic lesions of the brain, severe vascular dementia and cognitive impairment. Those patients' medical history showed recurrent transient abnormalities of cerebral blood flow and minor strokes-17 (20.48%) patients of whom 11 had CDR-2 and 6 had CDR-3; • A group with atherosclerotic (vascular) Parkinson's disease and manifestations of dementia-19 (22.89%) patients of whom 10 had CDR-1 and 9 had CDR-2; • A group with Binswanger's disease and manifestations of dementia-6 (7.23%) patients of whom 1 had CDR-1, 2 had CDR-2 and 3 had CDR-3; • A group with Parkinson's disease and manifestations of dementia-4 (4.82%) patients of whom 1 had CDR-1 and 3 had CDR-2.
RESULTS
Test Group
According to CT and MRI: • AD-specific neurodegenerative changes in the brain manifested in temporal lobes atrophy which at different stages of the disease lead to 4% -62% reduction in tissue mass were detected in 81 (100%) cases ( Table 1) ; • individual cerebral neurodegenerative changes were observed in a limited number of cases ( Table 1) . According to SG, the slowing of blood flow in the cerebral hemispheres was detected in 81 (100%) cases.
According to REG, pulse blood volume reduction in the carotid system was detected in 81 (100%) cases.
Elevated level of lipids in the blood was detected in 34 (41.98%) cases.
Hypercoagulation was observed in 37 (45.68%) cases.
• Absence (or they were poorly expressed) of atherosclerotic changes of extra and intracranial arteries-81 (100%) patients (Figures 1, 2 and 6 ); • Reduction of capillary contrast phase in the form of microvascular cone-shaped spots in the projection of the hippocampus and the fronto-parietal regions-81 (100%) patients (Figures 1-3 An analysis of 2 × 2 contingency tables for each of the parameters under study was made using the chi-square test which showed statistically significant differences for each of the parameters under study except for unocclusive hydrocephalus. 
Control Group
According to CT and MRI: • changes in the brain manifested in the local atrophy of the temporal lobes (specific to AD) were not identified in any case ( Table 1) ; • cerebral neurodegenerative changes were found in almost all cases ( Table 1) . According to SG, the slowing of blood flow in the cerebral hemispheres was detected in all 83 (100%) cases.
According to REG, pulse blood volume reduction in the carotid system was detected in all 83 (100%) cases. fronto-parietal regions were not detected in any case; • multiple arterio-venous shunts in the basin of the front villous artery and in the basin of the arterial branches supplying the fronto-parietal cerebral cortex were not detected in any case;
• some scattered areas of low capillary contrast at the level of the white matter of the brain-36 (43.37%) patients; • multiple scattered arterio-venous shunts at the level of the white matter of the brain-37 (44.58%) patients; • scattered, mainly in the white matter, early venous dumping-38 (45.78%) patients; • development of abnormally enhanced venous trunks and anomalous venous congestion was not detected in any case; • increased loop formation of distal intracranial arterial branches-5 (6,02%) patients. Thus, Control Group patients did not have any vascular and microcirculatory disorders of the brain similar to those detected among Test Group patients (Figures 7 and 8) .
DISCUSSION
For antemortem studies of the brain vascular system, cerebral MUGA has been used. Due to its specificity and high image resolution, the method allows to obtain high quality vascular imaging and provides an opportunity for stepwise study of the state of the arterial, capillary, venous bed and the architectonics of the existing arterial and venous shunts and blood flows [20, 21, 30, 32, 50] . By means of this method we were able to detect AD-specific disorders of blood circulation and microcirculation in the temporal and fronto-parietal brain regions among Test Group patients.
We have named those disorders "dyscirculatory angiopathy of Alzheimer's type" (DAAT) [32, 50] . They do not occur among Control Group patients, and they are specific for AD and non-specific for other neurodegenerative diseases accompanied by the development of dementia and cognitive impairment.
DAAT is the combination of the following: • reduction of the capillary bed in the temporal and fronto-parietal brain regions; • development of multiple arterio-venous shunts in the basin of the front villous artery supplying the hippocampus and in the basin of the arterial branches supplying the fronto-parietal brain regions; • early venous dumping of arterial blood through these shunts with simultaneous filling of the arteries and veins in the temporal and fronto-parietal regions; • development of abnormally enlarged lateral venous branches that receive blood from the arterio-venous shunts in the temporal and fronto-parietal region; • anomalous venous stasis on the border of the frontal and parietal lobe due to excessively high blood influx from the arterio-venous shunts; • increased loop formation of distal intracranial arterial branches.
In fact, DAAT is a vascular sign of AD and is an important criterion in the differential diagnosis of neurodegenerative diseases [21, 32, 50] .
The obtained data concerning the capillary disorders in AD is confirmed by morphological studies conducted by S. J. Baloiannis and I. S. Baloiannis [51] . These authors used electron microscopy to reveal capillary degeneration and a significant decrease in the number of capillaries per cubic centimeter of the hippocampus tissue in patients with AD compared to the hippocampus tissue in people of the same age but without the disease.
In our opinion, DAAT progress begins with abnormalities of the cerebral microcirculation which are manifested in capillary bed reduction which leads to the reduction of arterial blood flow to the cerebral tissues. The result of it is chronic hypoperfusion of the temporal and fronto-parietal regions which causes AD-specific brain tissue hypoxia; that is also supported by other authors' studies [28] . The process of capillary bed reduction is accompanied by a compensatory opening of arterio-venous shunts which relieve the arterial bed by dumping blood to the venous bed.
Such compensatory opening of arterio-venous shunts is observed in various human organs and tissues during the reduction of arterial blood flow-for example, in peripheral arterial occlusions [52] . Opening arterio-venous shunts cause arterio-venous dumping and allow to balance the inflow and outflow of blood to the site with reduced arterial or capillary permeability.
With AD, the overflow of arterial bed by venous blood leads to abnormal enlargement of the lateral veins of the temporal and fronto-parietal region and subsequent blood congestion.
These hemodynamic changes may in their turn affect An analysis of 2 × 2 contingency tables for each of the parameters under study was made using the chi-square test which showed statistically significant differences for each of the parameters under study. the metabolism of amyloid-beta and cause its deposition and accumulation in cerebral tissue thereby stimulating AD progression [21, 30, 32] . Our hypothesis is confirmed by the work by B. V. Zlokovic et al. [53, 54] in which the authors, carrying out research on genetically modified mice, have shown that an experimental model of AD is characterized by the accumulation of vasculotoxic and neurotoxic molecules in the brain tissue which causes hemodynamic instability, reduces capillary blood flow and promotes the development of specific cerebral hypoxia. This process leads to an increase in accumulation and a decrease in removal of beta amyloid, subsequent dysfunction and neurodegeneration.
The data obtained resonate with research by A. Dorr et al. [26] conducted on transgenic mice with an experimental model of AD. In the study of the material the authors revealed degeneration, diameter reduction and increased sinuosity of microvessels in the cortex of tested animals which was interpreted as the result of betaamyloid deposition in the vascular wall and parovazal tissue.
According to our results obtained among Test Group patients, the severity of arterial, venous, and microvascular abnormalities does not depend on the timing of the onset of AD symptoms, severity of dementia or severity of cognitive impairment [21, 30, 32] . These abnormalities are almost equally observed among patients with clinical AD stages (TDR-1, TDR-2, TDR-3) and among those with a preclinical AD stage (TDR-0). Moreover, similar changes occur among children of 8-12 years of age and among AD patients' children [55, 56] . It suggests that microvascular changes in the brain are likely to develop before the process of beta-amyloid deposition. It seems unlikely that in genetically determined and sporadic forms of AD, beta-amyloid deposition in the vascular wall and brain tissue starts early, decades before any clinical manifestations of the disease.
Interestingly, there are studies that show that the high content of amyloid-beta in the brain tissue can be observed in healthy people and does not always lead to dementia and AD [57] .
For antemortem studies of CBF and cerebral perfusion abnormalities in AD, SPECT, PET and MRI technologies are usually used being at present not sensitive enough to determine vascular and microcirculatory abnormalities, and therefore it is difficult to identify these abnormalities in 100% of cases [27, 58] . In contrast to MUGA, these technologies do not allow to visualize the vascular system of the brain and to explore its parts locally determining the state of the arteries, capillaries and veins. They allow to determine total perfusion in a certain area, lobe or in the whole brain.
However, studies using SPECT and PET have shown that progression of AD and cognitive impairment is characterized by a progressive decline of CBF in the temporal, parietal and frontal regions [27, 59] ; we have obtained similar results not only by means of MUGA but also by means of SG and REG.
When using Perfusion MRI technologies to determine cerebral perfusion, it should be noted that this method, though more progressive compared to SPECT and PET, also does not allow to determine the state of the local vascular system in certain areas of the cerebral tissue. As a result, as well as when using SPECT and PET, total perfusion is determined in some area or lobe of the brain. This particularity of Perfusion MRI technology has led to the appearance of reports describing compensatory enhancement of cerebral perfusion at preclinical and early AD stages but persistent hypoperfusion in the later stages of the disease [27] , which potentially confirms our data.
As we have already noted, DAAT progression leads to natural compensatory opening of arterio-venous shunts with sufficiently powerful dumping of arterial blood to the venous bed. Preclinical and early clinical AD stages progress at a younger age, when compensatory mechanisms regulating CBF are expressed better, the deposition of amyloid-beta in the brain tissue being quite small. In this case, when determining the perfusion by means of Perfusion MRI technology, total perfusion is visualized in the temporal lobes of the brain including the compensatory powerful dumping of arterial blood into the venous bed as well. As a result, the obtained numbers may exceed the norm. Obviously, that was what the authors have received interpreting it as enhanced perfusion due to more active work of arteries and capillaries. Late AD stages occur in old age, when compensatory mechanisms of CBF regulation decrease and there is high accumulation of amyloid-beta in the brain tissue which helps to reduce CBF. As a result, the authors have observed the phenomenon of cerebral hypoperfusion which confirms our data.
Vascular and microvascular changes in AD are always associated with a decrease in size and with atrophic phenomena in the temporal and fronto-parietal brain regions [32, [47] [48] [49] [50] . It is interesting to note that the tendency for temporal lobes size reduction has been reported in new-born babies who have a high potential risk for the disease, from which the authors conclude that these changes begin to progress in utero [60] .
These data indirectly confirm our hypothesis that DAAT is likely to develop before the deposition of amyloid-beta, its excretion process being affected, which may possibly lead to its accumulation. DAAT does not cause but only contributes to AD, and may perhaps be congenital in nature [55, 56] .
Thus, we can conclude that the reduction of the capillary bed, abnormal cerebral microcirculation, as well as the accumulation of amyloid-beta are interrelated processes that occur early enough, proceed for a long time, lead to hypotrophic and atrophic changes in the tissue of the temporal and fronto-parietal regions and finally cause AD.
The combination of these changes must be taken into consideration in the examination of patients with AD, the monitoring of the disease course and, naturally, in the development of new methods for treating AD [21, 28, 30, 32, 36, 42] .
